FilingReader Intelligence

Hengrui Medicine gets green light for clinical trials

February 27, 2025 at 05:08 PM UTCBy FilingReader AI

Jiangsu Hengrui Medicine (SSE:600276) announced that its subsidiaries, Suzhou Shengdiya Biomedical and Shanghai Shengdi Pharmaceutical, have been granted clinical trial approval for SHR-A2009 injection and adebrelimab injection by the National Medical Products Administration. The trials will assess the safety, tolerability, and efficacy of SHR-A2009 in combination with anti-tumor therapies for patients with advanced solid tumors. SHR-A2009, an anti-HER3 antibody-drug conjugate, has seen cumulative R&D investment of approximately RMB 114.6 million. Adebrelimab injection, a PD-L1 monoclonal antibody, has had cumulative R&D investment of approximately RMB 784.71 million. The company cautioned that the drug still needs to undergo clinical trials and regulatory review before it can be commercialized.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SSE:600276Shanghai Stock Exchange
Shanghai Blue Chip

News Alerts

Get instant email alerts when Jiangsu Hengrui Medicine publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →